Crossmark

Current status and future perspectives of HLA-edited induced pluripotent stem cells

Published Online: 2020-10-01

Published Print: 2020-12

Authors

Koga, Keiko

Wang, Bo

Kaneko, Shin http://orcid.org/0000-0003-2291-4586
License Information

Text and Data Mining valid from 2020-10-01

Version of Record valid from 2020-10-01
More Information

Article History

Received: 31 May 2020

Accepted: 1 July 2020

First Online: 1 October 2020

Ethics approval and consent to participate

: Not applicable

: Not applicable

: Shin Kaneko is a founder, shareholder, and chief scientific officer of Thyas Co., Ltd. and received research funding from Takeda Pharmaceutical Co. Ltd., Kirin Holdings Co., Ltd., Terumo Co. Ltd., TOSOH Co. Ltd., and Thyas Co., Ltd.Keiko Koga is an employee of Takeda Pharmaceutical Co. Ltd.

Document is current